Search

Background Psoriatic arthropathy is a progressive and debilitating disease involving reduction of functional activity of the articulations with consequent deterioration of the patient's quality of life. The entheses represent the initial site of articular inflammation and the enthesis of the Achilles tendon is the first to be affected. In some patients with psoriasis, enthesitis may not be diagnosed because it is still asymptomatic. Objectives To evaluate whether ultrasonography allows early diagnosis in a larger population and to identify significant alterations of enthesitis beyond increased thickness of the Achilles tendon. Materials and methods The study was undertaken on 59 patients (16 women, 43 men), with chronic plaque psoriasis and 59 patients with other dermopathies. The patients underwent echographic evaluation of the Achilles heel using a Voluson imaging system. The severity of the psoriasis was evaluated by the Psoriasis Area Severity Index and the enthesitis by the Glasgow Ultrasound Enthesitis Scoring System ( GUESS). Results The GUESS score was higher in those patients with psoriasis compared with patients with other dermopathies. Among psoriatic patients, 22% (13 of 59) presented tendon thickness over 5·29 mm and irregular tendon structure. Other abnormalities affected the tendon in 12 patients. In seven patients (12%) bursitis was also revealed. Conclusions Our data confirm that ultrasonography is a sensitive technique which reveals enthesitis more frequently than clinical examination in patients affected by psoriasis. We suggest the use of ultrasonography of the Achilles tendon in early diagnosis of psoriatic arthropathy with the objective of preventing progression of the pathology. [ABSTRACT FROM AUTHOR]

Poster: Clinical track: Gynaecological (endometrium, cervix, vagina, vulva) PO-1127: Acute and late toxicity report of postoperative IG-IMRT for gynecological malignancies M. La Vecchia, F. Cuccia, G. Ferrera, G. Mortellaro, D. Cespuglio, L. Ognibene, G. De Gregorio, N. Luca, G. Trapani, E. Quartuccio, A. Gioia, A. Palmeri, G. Terranova, G. Napoli, A. Sanfratello, C. LotÃ, M. Torchia, V. Venuti, V. Valenti, A. Tripoli, G. Evangelista, A. Lo Casto. [Extracted from the article]

• Oligometastatic sarcomas can be safely and effectively treated with SABR. • One out of 5 patients is free of progression at 2-years after SABR. • SABR can defer the need for systemic therapy with a median time of 19,5 months. Stereotactic Ablative Radiotherapy (SABR) is emerging as a valid alternative to surgery in the oligometastatic setting in soft tissue sarcomas (STS), although robust data are lacking. The aim of this study is to evaluate toxicity and efficacy of SABR in oligometastatic STS. This is a retrospective multicenter study including adult patients affected by stage IV STS, treated with SABR for a maximum of 5 cranial or extracranial metastases in up to 3 different organs. SABR was delivered with ablative purposes. Study endpoints were overall survival (OS), local control (LC), distant progression free survival (DPFS), time to polymetastatic progression (TTPP), time to new systemic therapy (TTNS) and toxicity. From 10 Italian RT centers, 138 patients (202 metastases) treated between 2010 and 2022 were enrolled in the study. Treatment was generally well tolerated, no acute or late toxicity ≥ G3 was recorded. Median follow up was 42.5 months. Median OS was 39.7 months. Actuarial OS at 1 and 2 years was 91.5 % and 72.7 %. Actuarial LC at 1 and 2 years was 94.8 % and 88.0 %. Median DPFS was 9.7 months. Actuarial DPFS at 1 and 2 years was 40.8 % and 19.4 %. SABR is a safe and effective approach for the treatment of oligometastatic sarcoma. One out of 5 patients is free of progression at 2-years. [ABSTRACT FROM AUTHOR]

Poster: Clinical track: Prostate PO-1165: Toxicity and outcomes of postoperative hypofractionated Helical Tomotherapy for prostate cancer F. Cuccia, G. Ferrera, V. Serretta, G. Mortellaro, F. Verderame, A. Lupo, D. Cespuglio, L. Ognibene, G. De Gregorio, E. Quartuccio, A. Gioia, M. La Vecchia, N. Luca, G. Trapani, V. Valenti, A. Tripoli, A. Lo Casto. [Extracted from the article]